CAMBRIDGE, Mass., Sept. 8, 2020 /PRNewswire/ -- Akebia
Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company
with the purpose to better the lives of people impacted by kidney
disease, today announced that it will participate in the following
virtual investor conferences in September.
- Citi's 15th Annual BioPharma Conference
John P. Butler, President and Chief Executive
Officer, to participate in virtual one-on-one meetings on
Wednesday, September 9.
- H.C. Wainwright 22nd Annual Global Investment
Conference
Michel Dahan,
Chief Operating Officer, and David
Spellman, Chief Financial Officer, to participate in a
virtual fireside chat on Monday, September
14, at 10:00 a.m. ET.
- Morgan Stanley Virtual 18th Annual Global
Healthcare Conference
John P.
Butler, President and Chief Executive Officer, to
participate in a fireside chat on Tuesday,
September 15, at 1:15 p.m.
ET.
- Cantor Virtual Global Healthcare
Conference
John P. Butler,
President and Chief Executive Officer, to present on Wednesday, September 16, at 1:20 p.m. ET.
Where applicable, live webcasts of Akebia's presentations will
be made available on the Investors section on the Company's website
at https://ir.akebia.com.
About Akebia Therapeutics
Akebia Therapeutics, Inc. is
a fully integrated biopharmaceutical company with the purpose to
better the lives of people impacted by kidney disease. The Company
was founded in 2007 and is headquartered in Cambridge, Massachusetts. For more
information, please visit our website at www.akebia.com, which does
not form a part of this release.
Akebia Therapeutics Contact
Kristen K. Sheppard, Esq.
ir@akebia.com
View original content to download
multimedia:http://www.prnewswire.com/news-releases/akebia-therapeutics-announces-september-2020-investor-conference-schedule-301125188.html
SOURCE Akebia Therapeutics